Definium Therapeutics (DFTX) Share-based Compensation (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Share-based Compensation of $11.5 million for Q1 2026, up 235.08% year-over-year from $3.4 million in Q1 2025, and up 373.01% quarter-over-quarter from $2.4 million in Q4 2025.
Definium Therapeutics (DFTX) Share-based Compensation (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Share-based Compensation for 6 consecutive years, with $11.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 235.08% year-over-year to $11.5 million; the TTM figure through Mar 2026 stood at $25.0 million (up 96.71% YoY), while the FY2025 annual figure was $5.9 million, up 10892.59% from the prior year.
- Share-based Compensation improved to $11.5 million in Q1 2026 per DFTX's latest filing, from $2.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $11.5 million in Q1 2026 and bottomed at $64000.0 in Q4 2023.
- Historically, Share-based Compensation has averaged $4.1 million across 5 years, with a median of $3.8 million in 2023.
- Annual changes were most pronounced in 2023 — Share-based Compensation sank 95.35% — and 2026, when it jumped 235.08%.
- Definium Therapeutics' Share-based Compensation stood at $1.4 million in 2022, then tumbled by 95.35% to $64000.0 in 2023, then soared by 5901.56% to $3.8 million in 2024, then sank by 36.81% to $2.4 million in 2025, then surged by 373.01% to $11.5 million in 2026.
- Business Quant data shows DFTX's Share-based Compensation at $11.5 million in Q1 2026, $2.4 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | 9.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.64 Mn |
| Jun 30, 2026 | 9.64 Mn |
| Mar 31, 2026 | 11.48 Mn |
| Mar 31, 2026 | 11.48 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Sep 30, 2025 | 5.82 Mn |
| Sep 30, 2025 | 5.82 Mn |
| Jun 30, 2025 | 5.25 Mn |
| Jun 30, 2025 | 5.25 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Sep 30, 2024 | 3.84 Mn |
| Sep 30, 2024 | 3.84 Mn |
| Jun 30, 2024 | 5.43 Mn |
| Jun 30, 2024 | 5.43 Mn |
| Mar 31, 2024 | 1.67 Mn |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 64,000.00 |
| Dec 31, 2023 | 64,000.00 |